VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

As of April 22, 2024, VRTX stock price climbed to $399.92 with 1,246,726 million shares trading.

VRTX has a beta of 0.84, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.18 to the broad based SPY ETF.

VRTX has a market cap of $103.30 billion. This is considered a Large Cap stock.

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.20 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.10.

In the last 3 years, VRTX stock traded as high as $448.40 and as low as $176.36.

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): RAYD, VTI, VOO, QQQ, SPY.

VRTX has underperformed the market in the last year with a return of +20.8%, while the SPY ETF gained +22.9%. In the last 3 month period, VRTX fell short of the market, returning -9.1%, while SPY returned +3.7%. However, in the most recent 2 weeks VRTX has outperformed the stock market by returning -1.1%, while SPY returned -3.7%.

VRTX support price is $389.25 and resistance is $399.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX stock will trade within this expected range on the day.